Thomas Gad | Founder, Interim CEO and President |
Bo Kruse | CFO |
Sue Smith | Chief Commercial Officer |
Vignesh Rajah | Chief Medical Officer |
Dr. Steen Lisby | Chief Scientific Officer |
Alec Stranahan | Bank of America |
Joseph Thome | Cowen & Company |
Charles Zhu | Guggenheim |
Mike Ulz | Morgan Stanley |
Tessa Romero | JP Morgan |
Sebastiaan van der Schoot | Kempen |
Good day, and welcome to the Y-mAbs Therapeutics, Inc.’s Earnings Conference Call for the First Quarter of 2022. Today’s conference is being recorded.
Let me quickly remind you that the following discussion contains certain forward-looking -- certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company’s annual report on the Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 1, 2022. At this time, I would now like to turn the conference over to Thomas Gad, the Company’s Founder, Interim CEO and President.